Drugs / Streptokinase
Streptokinase
also known as
Estreptoquinasa · Fibrinolytic Therapy · Kabikinase · Streptase · Streptase (Streptokinase) · Streptokinase c
Protein / enzyme biologic targets PLG via activation
Trials 10 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT01641549 Comparator | Apr 2017 → Mar 2019 | cardiac valvular defect | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01305226 Comparator | Oct 2010 → Aug 2011 | acute myocardial infarction | Bharat Biotech International Limited | Completed | No outcome recorded |
| Phase 3 | NCT00232622 Comparator | Nov 2004 → Mar 2007 | — | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02182011 Comparator | May 2000 → Jun 2001 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07360717 Comparator | Nov 2024 → Dec 2025 | — | U. N. Mehta Institute of Cardiology and Research Center | Completed | No outcome recorded |
| — | NCT07374978 Comparator | Jul 2023 → May 2025 | pulmonary embolism | Ain Shams University | Completed | No outcome recorded |
| — | NCT03595085 Comparator | Sep 2018 → Oct 2020 | pulmonary embolism | Assiut University | Unknown | No outcome recorded |
| — | NCT03583931 Comparator | Jul 2018 → Feb 2020 | blood coagulation disease, pleural empyema, pleuropneumonia | Denver Health and Hospital Authority | Completed | No outcome recorded |
| — | NCT01451320 Comparator | Jan 1993 → Dec 2009 | — | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Streptokinase | “Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be...” NCT03677466 ↗17“Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses” NCT01641549 ↗ “streptokinase, 250,000 units” NCT00302419 ↗ |
| Known as | Estreptoquinasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108147 ↗ |
| Known as | Fibrinolytic Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03583931 ↗ |
| Known as | Kabikinase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108147 ↗ |
| Known as | Streptase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108147 ↗ |
| Known as | Streptase (Streptokinase) | “Streptase (Streptokinase)” NCT00627809 ↗ |
| Known as | Streptokinase c | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108147 ↗ |
| Action | Activate | “can bind and activate human plasminogen” NCT01977118 ↗1“Plasminogen activator” CHEMBL2108147 ↗ |
| Modality | Protein / enzyme biologic | “Streptokinase is a protein secreted by several species of streptococci” NCT01977118 ↗ |
| Route | Other | “intracoronary infusion of streptokinase” NCT00000503 ↗ |
| Target | PLG | “Plasminogen activator” CHEMBL2108147 ↗ |